false 0001347178 0001347178 2025-02-18 2025-02-18 0001347178 us-gaap:CommonStockMember 2025-02-18 2025-02-18 0001347178 vnda:SeriesAJuniorParticipatingPreferredStockPurchaseRightMember 2025-02-18 2025-02-18

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 20, 2025 (February 18, 2025)

 

 

VANDA PHARMACEUTICALS INC.

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware   001-34186   03-0491827
(State or other jurisdiction
of incorporation)
  (Commission
File No.)
  (IRS Employer
Identification No.)

2200 Pennsylvania Avenue NW

Suite 300E

Washington, DC 20037

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (202) 734-3400

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, par value $0.001 per share   VNDA   The Nasdaq Global Market
Series A Junior Preferred Stock Purchase
Right, par value $0.001 per share
    The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 18, 2025, the Compensation Committee (the “Compensation Committee”) of the Board of Directors of Vanda Pharmaceuticals Inc. (the “Company”) awarded 2024 annual bonuses and approved 2025 annual base salaries and 2025 bonus target amounts for the Company’s named executive officers. Prior to approving the foregoing, the Compensation Committee reviewed an analysis of the Company’s executive compensation compared to the Company’s peer group conducted by Willis Towers Watson, a compensation consultant engaged by the Compensation Committee.

The Compensation Committee awarded bonuses for performance for the twelve-month period ended December 31, 2024 in the amounts set forth opposite the names of the executive officers listed below.

 

Name

  

Position

  

2024 Bonus

 

Mihael Polymeropoulos, M.D.

   President, Chief Executive Officer and Chairman of the Board    $ 947,928  

Kevin Moran

   Senior Vice President, Chief Financial Officer and Treasurer    $ 309,181  

Gunther Birznieks

   Senior Vice President, Business Development    $ 309,181  

Timothy Williams

   Senior Vice President, General Counsel and Secretary    $ 309,181  

Joakim Wijkstrom

   Senior Vice President, Chief Marketing Officer    $ 320,040  

The Compensation Committee approved 2025 annual base salaries and 2025 bonus target amounts for the twelve-month period ending December 31, 2025 in the amounts set forth opposite the names of the executive officers listed below.

 

Name

  

Position

  

2025 Base Salary

    

2025 Target Bonus

 

Mihael Polymeropoulos, M.D.

   President, Chief Executive Officer and Chairman of the Board    $ 965,655        80

Kevin Moran

   Senior Vice President, Chief Financial Officer and Treasurer    $ 559,935        45

Gunther Birznieks

   Senior Vice President, Business Development    $ 559,935        45

Timothy Williams

   Senior Vice President, General Counsel and Secretary    $ 559,935        45

Joakim Wijkstrom

   Senior Vice President, Chief Marketing Officer    $ 579,600        45

In addition, the Compensation Committee granted restricted stock unit (“RSU”) awards under the Company’s Amended and Restated 2016 Equity Incentive Plan, as amended, to its named executive officers in the amounts set forth opposite the names of the executive officers listed below. The RSUs for all named executive officers will vest in four equal annual installments beginning on March 1, 2026.

 

Name

  

Position

  

Number of Shares Underlying RSU Award

 

Mihael Polymeropoulos, M.D.

   President, Chief Executive Officer and Chairman of the Board      450,000  

Kevin Moran

   Senior Vice President, Chief Financial Officer and Treasurer      125,000  

Gunther Birznieks

   Senior Vice President, Business Development      125,000  

Timothy Williams

   Senior Vice President, General Counsel and Secretary      125,000  

Joakim Wijkstrom

   Senior Vice President, Chief Marketing Officer      125,000  


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: February 20, 2025     VANDA PHARMACEUTICALS INC.
    By:  

/s/ Timothy Williams

    Name:   Timothy Williams
    Title:   Senior Vice President, General Counsel and Secretary
v3.25.0.1
Document and Entity Information
Feb. 18, 2025
Document And Entity Information [Line Items]  
Amendment Flag false
Entity Central Index Key 0001347178
Document Type 8-K
Document Period End Date Feb. 18, 2025
Entity Registrant Name VANDA PHARMACEUTICALS INC.
Entity Incorporation State Country Code DE
Entity File Number 001-34186
Entity Tax Identification Number 03-0491827
Entity Address, Address Line One 2200 Pennsylvania Avenue NW
Entity Address, Address Line Two Suite 300E
Entity Address, City or Town Washington
Entity Address, State or Province DC
Entity Address, Postal Zip Code 20037
City Area Code (202)
Local Phone Number 734-3400
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol VNDA
Security Exchange Name NASDAQ
Series A Junior Participating Preferred Stock Purchase Right [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Series A Junior Preferred Stock PurchaseRight, par value $0.001 per share
Trading Symbol
Security Exchange Name NASDAQ

Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025 Vanda Pharmaceuticals 차트를 더 보려면 여기를 클릭.
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025 Vanda Pharmaceuticals 차트를 더 보려면 여기를 클릭.